Novel and Traditional Risk Factors for Symptomatic PAD in Women
女性症状性 PAD 的新的和传统的危险因素
基本信息
- 批准号:7384412
- 负责人:
- 金额:$ 13.64万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2006
- 资助国家:美国
- 起止时间:2006-03-20 至 2011-02-28
- 项目状态:已结题
- 来源:
- 关键词:Alcohol consumptionAlteplaseAmericanAntigensAntioxidantsApolipoproteinsApolipoproteins BAreaAspirinAtherosclerosisAwardBehavioralBiological MarkersBloodBlood BanksBlood PressureBlood specimenBody fatBostonC-reactive proteinCarbohydratesCardiovascular DiseasesCardiovascular systemCarotenoidsClinicalControlled Clinical TrialsCreatinineCross-Sectional StudiesDataData CollectionDevelopmentDiabetes MellitusDiet ModificationDietary FiberDiseaseDoseEnrollmentEnvironmentEpidemiologic StudiesEpidemiologyEvaluationFatty acid glycerol estersFellowshipFibrin fragment DFibrinogenFolateFoundationsFundingGlycosylated hemoglobin AGrantGroup ProcessesHealth ProfessionalHigh Density Lipoprotein CholesterolHomocysteineHomocystineHospitalsIncidenceInflammationIntakeIntercellular adhesion molecule 1Intermittent ClaudicationInterventionKnowledgeLife StyleLipoprotein (a)Lipoprotein (a-)Low-Density LipoproteinsLower ExtremityMalignant NeoplasmsMeasurementObesityOperative Surgical ProceduresParticipantPatient Self-ReportPeripheralPeripheral arterial diseasePhysical activityPlacebo ControlPlasmaPopulationPostdoctoral FellowPreventionPreventive MedicinePrimary PreventionProcessProtein CPublishingRandomizedRangeRenal functionResearchResearch ActivityResearch PersonnelRiskRisk AssessmentRisk EstimateRisk FactorsSample SizeScientistSmokingSourceSystemThrombosisTimeTrainingUnited States National Institutes of HealthVitamin B ComplexVitamin EWomanWomen&aposs Healthagedbasecardiovascular disorder preventioncardiovascular risk factorcareercohortcostdesigndietary antioxidantfollow-upinterestlipid metabolismmenmiddle agemodifiable risknon-diabeticnovelprogramsprospectiverepositoryskills
项目摘要
This project will prepare the candidate, Dr. Aruna Pradhan, for a career as an independent clinical scientist in
cardiovascular epidemiology with a focus on risk assessment of peripheral arterial disease (PAD), her area
of scientific interest. At the time of award activation, Dr. Pradhan will be a board eligible cardiologist having
completed her fellowship training at the Brigham and Women's Hospital (BWH), Boston. Her post-doctoral
research activities have been undertaken in the Center for Cardiovascular Disease Prevention within the
Division of Preventive Medicine, BWH. The Center provides a scientifically productive environment for the
support of junior investigators in the conduct of population-based epidemiologic research. The applicant
proposes a 5-year program of research that will prospectively evaluate novel and traditional risk factors for
PAD in women, among whom limited epidemiologic data exist. The risk factors to be examined may be
categorized into one of three groups: novel biomarkers, traditional and behavioral cardiovascular risk
factors, and dietary influences. Employing a prospective cohort design, analyses will be conducted in the
Women's Health Study of 39,876 healthy middle-aged American women. The long-term follow-up and high-
quality covariate data in this cohort offer a unique opportunity to study, in a prospective manner, potentially
modifiable risk factors for PAD in a large well-characterized population of women. At the conclusion of the
award period, Dr. Pradhan will have acquired advanced epidemiologic skills and expertise in the study of
PAD which will enable her to independently conduct research in prevention and treatment of this disease.
This proposal seeks to evaluate the association between a broad range of emerging and traditional risk
factors and the development of atherosclerosis in the lower extremity arterial system among American
women. While prior limited data are available pertaining to these risk factors in men, information with regard
to risk factor relationships in women are extremely sparse. Specific exposures of interest include blood-
based biomarkers, traditional cardiovascular risk factors such as diabetes, obesity, and elevated blood
pressure, behavioral risk factors such as smoking and physical inactivity, and dietary influences such as fat,
antioxidant, and carbohydrate intake.
该项目将为候选人Aruna Pradhan博士作为独立临床科学家的职业生涯做好准备,
心血管流行病学,重点是外周动脉疾病(PAD)的风险评估,她的领域
科学兴趣。在奖励激活时,Pradhan博士将成为符合董事会资格的心脏病专家,
在波士顿布里格姆妇女医院(BWH)完成了她的奖学金培训。她的博士后
研究活动已在心血管疾病预防中心进行,
预防医学部,BWH。该中心提供了一个科学的生产环境,
支持初级研究人员进行基于人群的流行病学研究。申请人
提出了一项为期5年的研究计划,将前瞻性地评估新的和传统的风险因素,
妇女的PAD,其中流行病学数据有限。要检查的风险因素可能是
分为三组:新的生物标志物,传统和行为心血管风险
因素和饮食影响。采用前瞻性队列设计,将在
女性健康研究:39,876名健康的美国中年女性长期跟踪和高-
该队列中的高质量协变量数据提供了一个独特的机会,以前瞻性的方式研究,
在大量特征明确的女性人群中,PAD的可改变风险因素。结束时
在获奖期间,Pradhan博士将获得先进的流行病学技能和专业知识,
这将使她能够独立进行预防和治疗这种疾病的研究。
该提案旨在评估广泛的新兴风险和传统风险之间的关联
美国人下肢动脉系统动脉粥样硬化的发病因素
妇女虽然先前关于男性这些风险因素的数据有限,但关于以下方面的信息
女性中与危险因素的关系非常稀少。特别关注的暴露包括血液-
基于生物标志物,传统的心血管危险因素,如糖尿病,肥胖,和血液
压力,行为风险因素,如吸烟和缺乏身体活动,以及饮食影响,如脂肪,
抗氧化剂和碳水化合物的摄入。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Aruna Das Pradhan其他文献
HYPERTRIGLYCERIDEMIA, INFLAMMATION, HYPERCHOLESTEROLEMIA, AND FUTURE CARDIOMETABOLIC DISEASE RISK: A DATA DRIVEN CLUSTER ANALYSIS IN THE WOMEN's HEALTH STUDY
- DOI:
10.1016/s0735-1097(20)32490-6 - 发表时间:
2020-03-24 - 期刊:
- 影响因子:
- 作者:
Edward Duran;Nancy R. Cook;Aaron W. Aday;Julie E. Buring;Paul M. Ridker;Aruna Das Pradhan - 通讯作者:
Aruna Das Pradhan
Effect of Pemafibrate on Diabetic Foot Ulceration and Gangrene: An Exploratory Analysis From PROMINENT
- DOI:
10.1016/j.jacc.2024.05.028 - 发表时间:
2024-07-23 - 期刊:
- 影响因子:
- 作者:
Lucas L. Marinho;Brendan M. Everett;Aaron W. Aday;Frank L.J. Visseren;Jean G. MacFadyen;Elaine Zaharris;Jorge Plutzky;Raul D. Santos;Peter Libby;Jean-Charles Fruchart;Paul M Ridker;Aruna Das Pradhan - 通讯作者:
Aruna Das Pradhan
STAGES OF ALBUMINURIA AND CARDIORENAL RISK IN TYPE 2 DIABETES - INSIGHTS FROM THE PROMINENT TRIAL
2 型糖尿病中蛋白尿阶段与心肾风险——来自重要试验的见解
- DOI:
10.1016/s0735-1097(25)00906-4 - 发表时间:
2025-04-01 - 期刊:
- 影响因子:22.300
- 作者:
Amanda Siqueira;Robert J. Glynn;Frank LJ Visseren;Jean G. MacFadyen;Elaine Zaharris;Peter Libby;Aruna Das Pradhan;Paul M. Ridker;Brendan Everett - 通讯作者:
Brendan Everett
CHANGES IN APOLIPOPROTEIN B AND LOW-DENSITY LIPOPROTEIN CHOLESTEROL AND CARDIOVASCULAR EVENTS WITH PEMAFIBRATE THERAPY
使用非诺贝特治疗对载脂蛋白 B、低密度脂蛋白胆固醇和心血管事件的变化
- DOI:
10.1016/s0735-1097(25)00941-6 - 发表时间:
2025-04-01 - 期刊:
- 影响因子:22.300
- 作者:
Brendan Everett;Robert J. Glynn;Frank Visseren;Jean G. MacFadyen;Elaine Zaharris;Amanda Siqueira;Jorge Plutzky;Raul Santos;Peter Libby;Aruna Das Pradhan;Paul M. Ridker - 通讯作者:
Paul M. Ridker
TRIGLYCERIDE-RICH LIPOPROTEIN PARTICLES, RACE/ETHNIC GROUP AND FUTURE CARDIOVASCULAR EVENTS:THE MESA STUDY
- DOI:
10.1016/s0735-1097(22)02544-x - 发表时间:
2022-03-08 - 期刊:
- 影响因子:
- 作者:
Edward Duran;David R. Jacobs;Aruna Das Pradhan;Aaron W. Aday;Daniel A. Duprez - 通讯作者:
Daniel A. Duprez
Aruna Das Pradhan的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Aruna Das Pradhan', 18)}}的其他基金
Anti-inflammatory Therapy with Low Dose Methotrexate for Reduction of PAD
小剂量甲氨蝶呤抗炎治疗可减少 PAD
- 批准号:
9272427 - 财政年份:2014
- 资助金额:
$ 13.64万 - 项目类别:
Anti-inflammatory Therapy with Low Dose Methotrexate for Reduction of PAD
小剂量甲氨蝶呤抗炎治疗可减少 PAD
- 批准号:
8738800 - 财政年份:2014
- 资助金额:
$ 13.64万 - 项目类别:
Anti-inflammatory Therapy with Low Dose Methotrexate for Reduction of PAD
小剂量甲氨蝶呤抗炎治疗可减少 PAD
- 批准号:
8913257 - 财政年份:2014
- 资助金额:
$ 13.64万 - 项目类别:
Mechanisms of Statin-Induced DM in JUPITER (Rosuvasatin for CVD Prevention)
JUPITER 中他汀类药物诱发 DM 的机制(用于预防 CVD 的瑞舒伐他汀)
- 批准号:
8286969 - 财政年份:2010
- 资助金额:
$ 13.64万 - 项目类别:
Diabetes Prevention in the Vitamin D and Omega-3 Trial
维生素 D 和 Omega-3 试验中的糖尿病预防
- 批准号:
8516502 - 财政年份:2010
- 资助金额:
$ 13.64万 - 项目类别:
Mechanisms of Statin-Induced DM in JUPITER (Rosuvasatin for CVD Prevention)
JUPITER 中他汀类药物诱发 DM 的机制(用于预防 CVD 的瑞舒伐他汀)
- 批准号:
7946012 - 财政年份:2010
- 资助金额:
$ 13.64万 - 项目类别:
Mechanisms of Statin-Induced DM in JUPITER (Rosuvasatin for CVD Prevention)
JUPITER 中他汀类药物诱发 DM 的机制(用于预防 CVD 的瑞舒伐他汀)
- 批准号:
8507268 - 财政年份:2010
- 资助金额:
$ 13.64万 - 项目类别:
Diabetes Prevention in the Vitamin D and Omega-3 Trial
维生素 D 和 Omega-3 试验中的糖尿病预防
- 批准号:
8689001 - 财政年份:2010
- 资助金额:
$ 13.64万 - 项目类别:
Mechanisms of Statin-Induced DM in JUPITER (Rosuvasatin for CVD Prevention)
JUPITER 中他汀类药物诱发 DM 的机制(用于预防 CVD 的瑞舒伐他汀)
- 批准号:
8123463 - 财政年份:2010
- 资助金额:
$ 13.64万 - 项目类别:
Novel and Traditional Risk Factors for Symptomatic PAD in Women
女性症状性 PAD 的新的和传统的危险因素
- 批准号:
7762747 - 财政年份:2006
- 资助金额:
$ 13.64万 - 项目类别:
相似海外基金
AcT-Cog: Online cognitive assessment in the Alteplase compared to Tenecteplase (AcT) trial.
AcT-Cog:阿替普酶与替奈普酶 (AcT) 试验相比的在线认知评估。
- 批准号:
444794 - 财政年份:2021
- 资助金额:
$ 13.64万 - 项目类别:
Operating Grants
INTERRAcT: Thrombus characteristics for predicting Reperfusion with Alteplase compared to Tenecteplase
INTERRAcT:与替奈普酶相比,阿替普酶预测再灌注的血栓特征
- 批准号:
433102 - 财政年份:2020
- 资助金额:
$ 13.64万 - 项目类别:
Operating Grants
Alteplase Compared to Tenecteplase in patients with Acute Ischemic Stroke: QuICR & OPTIMISE Registry based Pragmatic Randomized Controlled Trial
阿替普酶与替奈普酶治疗急性缺血性中风患者的比较:QuICR
- 批准号:
401715 - 财政年份:2019
- 资助金额:
$ 13.64万 - 项目类别:
Operating Grants
Tenecteplase versus Alteplase for Stroke Thrombolysis Evaluation (TASTE) Trial
替奈普酶与阿替普酶用于中风溶栓评估 (TASTE) 试验
- 批准号:
nhmrc : 1079696 - 财政年份:2015
- 资助金额:
$ 13.64万 - 项目类别:
Project Grants
Tenecteplase versus Alteplase for Stroke Thrombolysis Evaluation (TASTE) Trial
替奈普酶与阿替普酶用于中风溶栓评估 (TASTE) 试验
- 批准号:
nhmrc : GNT1079696 - 财政年份:2015
- 资助金额:
$ 13.64万 - 项目类别:
Project Grants
Low-Dose Tenecteplase vs Standard-Dose Alteplase for Acute Ischaemic Stroke: An Imaging Based Safety and Efficacy Study
低剂量替奈普酶与标准剂量阿替普酶治疗急性缺血性中风:一项基于影像学的安全性和有效性研究
- 批准号:
nhmrc : 510722 - 财政年份:2008
- 资助金额:
$ 13.64万 - 项目类别:
NHMRC Project Grants
Treatment of Deep Vein Thrombosis of the Lower Extremities w/Low Dose Alteplase
小剂量阿替普酶治疗下肢深静脉血栓
- 批准号:
8565339 - 财政年份:
- 资助金额:
$ 13.64万 - 项目类别:
Treament of Deep Vein Thrombosis of the Lower Extremities w/Low Dose Alteplase
小剂量阿替普酶治疗下肢深静脉血栓
- 批准号:
7593114 - 财政年份:
- 资助金额:
$ 13.64万 - 项目类别:
Treatment of Deep Vein Thrombosis of the Lower Extremities w/Low Dose Alteplase
小剂量阿替普酶治疗下肢深静脉血栓
- 批准号:
8952839 - 财政年份:
- 资助金额:
$ 13.64万 - 项目类别:














{{item.name}}会员




